Enochian Biosciences Acquires an Exclusive License for a Novel HENOB: Enochian Biosciences, Inc.
2020-02-03 07:30:10
Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
Key stats
Market capitalization
55.555MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.0402USD
About Enochian Biosciences, Inc
ISIN
US29350E1047
Sector
Health Technology
Industry
Biotechnology
Website
enochianbio.com
CEO
Mark Richard Dybul
Headquarters
Los Angeles
Employees
22
Founded
2011
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0